Login to Your Account

Merck returns phase II MS drug to Apitope

By Cormac Sheridan
Staff Writer

Monday, October 17, 2016

DUBLIN – Merck KGaA is terminating its interest in ATX-MS-1467 just ahead of a read-out from a phase II trial in multiple sclerosis and is handing back global rights to its original developer Apitope International NV.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription